{"filings":[{"id":95001,"accession_number":"0001723128-26-000019","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amneal Q1 2026 net revenue $723M (+4% YoY), GAAP net income $62M, adj. diluted EPS $0.27","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $723M (+4% YoY); GAAP net income $62M vs. $12M in Q1 2025; diluted EPS $0.19.","Adjusted EBITDA $202M (+19% YoY); adjusted diluted EPS $0.27 (+29% vs. $0.21).","Specialty revenue +23% driven by CREXONT, BREKIYA autoinjector, and UNITHROID; Affordable Medicines +2%.","AvKARE revenue -4% as government channel growth offset decline in low-margin distribution.","Affirms previously announced increase in full year 2026 guidance; results matched preliminary numbers from April 22."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":722519000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95000,"accession_number":"0001628280-26-032137","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amneal shareholders approve all proposals at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; Chintu Patel received ~270.4M votes (highest).","Advisory say-on-pay passed with ~96.5% support (269.1M for, 2.58M against).","Ernst & Young LLP ratified as auditor for fiscal 2026 with 293.2M votes for.","Broker non-votes on director election and say-on-pay totaled 21.95M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94999,"accession_number":"0001193125-26-168231","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","9.01"],"status":"ready","headline":"Amneal acquires Kashiv BioSciences for $750M upfront; raises FY2026 guidance on strong Q1","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Kashiv: $375M cash + $375M equity (28.9M shares) at close; up to $350M regulatory milestones plus royalties.","Expected close H2 2026; subject to shareholder and regulatory approvals; creates global biosimilar platform.","Preliminary Q1 2026 results strong; standalone FY2026 guidance raised (details per press release).","Transaction expected to deliver $400M-$500M in financial benefits; minimal impact on leverage.","Restrictive covenants agreements with co-CEOs Chirag and Chintu Patel from closing through fifth anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107765,"accession_number":"0001723128-26-000008","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal reports Q4 2025 net revenue $814M (+11% YoY); FY25 rev $3.02B; 2026 guidance $3.05-$3.15B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net revenue $814M (+11% YoY); GAAP net income $35M; diluted EPS $0.11.","Full year 2025 net revenue $3.02B (+8% YoY); GAAP net income $72M; diluted EPS $0.22.","Adjusted EBITDA FY25 $688M (+10% YoY); Q4 adj EBITDA $175M.","FY25 adj diluted EPS $0.83 vs $0.58 prior year; Q4 adj EPS $0.21 vs $0.12.","2026 guidance: net revenue $3.05-$3.15B, adj EBITDA $720-$760M, adj EPS $0.93-$1.03."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":3018760000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107764,"accession_number":"0001628280-26-004738","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Amneal reprices $2.1B term loan, margin cut 50 bps, saving ~$11M/year","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repricing amendment reduces interest rate margin by 50 bps to SOFR+3.00% or Base Rate+2.00%.","Total Amendment No. 2 Term Loans of ~$2.095B, including ~$134.7M new term loan.","Annualized cash interest savings estimated at ~$11 million.","Maturity unchanged at August 1, 2032.","Proceeds used to refinance existing Amendment No. 1 Term Loans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107763,"accession_number":"0001628280-26-003842","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Amneal Pharmaceuticals makes effective opioid settlement with states and subdivisions","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Amneal determined to make effective its Nationwide Opioids Settlement Agreement on Jan 29, 2026, with sufficient state and subdivision participation.","Company will pay $88.5 million to participating states and subdivisions.","Company will provide up to $177.4 million in naloxone nasal spray (valued at $125 per twin pack) to treat opioid overdoses.","Settling parties can opt for cash up to $44.4 million (25% of product value) during last four years of ten-year term, potentially raising total cash to $132.9 million."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107762,"accession_number":"0001723128-26-000003","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01"],"status":"ready","headline":"Amneal expects to meet or exceed FY2025 guidance; net leverage improves to 3.6x","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue guidance $3.0B-$3.1B; Adj EBITDA $675M-$685M; Adj diluted EPS $0.75-$0.80.","Operating cash flow guided at $300M-$330M; capex ~$100M","Net leverage estimated at 3.6x as of Dec 31, 2025, down from 3.9x at Dec 31, 2024.","Company reaffirms guidance originally provided on Oct 30, 2025; expects to meet or exceed targets."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":3018760000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124145,"accession_number":"0001723128-25-000059","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q3 revenue $785M (+12% YoY); GAAP EPS $0.01, adj. EPS $0.17; updated FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $785M (+12% YoY); GAAP net income $2M vs loss of $0.2M; diluted EPS $0.01.","Adjusted EBITDA $160M (+1% YoY); adjusted diluted EPS $0.17 (+6% YoY from $0.16).","Specialty +8% driven by CREXONT and UNITHROID; Affordable Medicines +8%; AvKARE +24%.","Incurred $22.5M milestone for XOLAIR biosimilar BLA submission; updated FY2025 guidance.","Launched BREKIYA autoinjector for migraine in October 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":2204441000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140820,"accession_number":"0001723128-25-000037","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q2: rev $725M (+3%), adj EBITDA $184M (+13%), raises FY25 guidance, refi debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $725M, up 3% YoY; GAAP net income $22M vs $6M in Q2 2024.","Adjusted EBITDA $184M (+13%); adjusted diluted EPS $0.25 (+56% from $0.16).","Specialty revenue +23% driven by CREXONT, RYTARY, UNITHROID; Affordable Medicines +1%.","Raising full-year 2025 guidance; completed oversubscribed debt refinancing extending maturities to 2032.","FDA approved Brekiya autoinjector for migraine; strong CREXONT Parkinson's uptake."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":1419928000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140815,"accession_number":"0001723128-25-000040","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K/A","filed_at":"2025-08-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amneal board adopts annual say-on-pay votes following stockholder preference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders recommended annual frequency for advisory say-on-pay votes; board agreed on August 5, 2025.","Future say-on-pay votes will be held annually until next frequency vote, due no later than 2031 annual meeting.","Amendment corrects cover-page date of original 8-K filed May 8, 2025 to May 6, 2025.","No other changes to original; matter is non-binding advisory vote on executive compensation frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140819,"accession_number":"0000950103-25-009701","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Amneal completes $2.7B refinancing: $2.1B term loan and $600M notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowed $2.1B of new seven-year term B loans due Aug 2032; margin SOFR+3.50% or base+2.50%.","Issued $600M 6.875% senior secured notes due Aug 2032; proceeds used to refinance existing debt.","Amended ABL facility extends maturity to Aug 2030; $600M revolving commitments unchanged.","Refinanced existing $2.26B term loans in full and repaid all ABL borrowings with net proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140818,"accession_number":"0000950103-25-009253","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Amneal prices $600M 6.875% senior secured notes due 2032, upsizes term loan to $2.1B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$600M notes priced at par with 6.875% coupon, due 2032; downsized from $750M due to term loan increase.","New term B loans upsized to $2.1B from $1.8B, seven-year maturity.","Proceeds to refinance existing term B loans in full and repay ABL facility.","Closing expected August 1, 2025, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140817,"accession_number":"0001723128-25-000033","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Amneal prelim Q2 revenue $720M-$730M, adj EBITDA $180M-$185M; director resigns","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $720M-$730M (+3% YoY); income before taxes $45M-$56M vs $20M in Q2 2024.","Adjusted EBITDA $180M-$185M (+13% YoY); gross leverage 3.8x, net leverage 3.7x.","Director Emily Peterson Alva resigned July 16 after Amneal Group ownership dropped below majority of Class A common stock.","Brekiya autoinjector approved for migraine/cluster headache; CREXONT uptake strong; biosimilar to XOLAIR BLA expected Q4 2025.","Full year 2025 guidance expected to be met or exceeded based on year-to-date performance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":1419928000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140816,"accession_number":"0000950103-25-009025","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Amneal seeks $1.8B new term loans and $750M notes to refinance debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amneal subsidiary seeks $1.8B in new seven-year term B loans to refinance existing term loans.","Launching $750M private offering of senior secured notes due 2032.","Proceeds to repay existing term B loans in full and a portion of ABL borrowings.","Notes offering not conditioned on the new term loan facility.","Transactions subject to market conditions; no assurance of completion or final terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158557,"accession_number":"0001723128-25-000024","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"All Amneal director nominees elected, say-on-pay approved at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["11 directors elected with overwhelming support; Paul Meister received lowest 'For' count at 239.8M shares.","Advisory vote on executive compensation passed with 258.8M votes for vs 1.3M against.","Stockholders selected 1 year as frequency for future say-on-pay votes (255.1M votes for 1 year).","Ratification of Ernst & Young as auditor for FY2025 approved with 289.0M votes for, 0.5M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158556,"accession_number":"0001723128-25-000018","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q1 revenue $695M (+5% YoY), net income $12M vs loss, adj EPS $0.21 (+50%), reaffirms guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $695M, up 5% YoY; GAAP net income $12M vs $92M loss in Q1 2024; diluted EPS $0.04 vs ($0.30).","Adjusted EBITDA $170M (+12% YoY); adjusted diluted EPS $0.21 (+50% from $0.14).","Affordable Medicines +6%, Specialty +3%, AvKARE +6%; CREXONT and injectable momentum cited.","Company reaffirms 2025 full-year guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":695420000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176949,"accession_number":"0001723128-25-000014","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Amneal promotes Jason Daly to EVP, Chief Legal Officer; base salary $575k","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Promoted from SVP to EVP, Chief Legal Officer & Corporate Secretary, effective March 1, 2025.","Employment agreement includes initial term through March 31, 2027, with auto-renewal.","Annual base salary of $575,000; bonus target 55% of base with performance multiplier 0-150%.","Severance: 150% of salary, prorated bonus, 18-month benefits, and 12-month outplacement.","Change-in-control protection: equity vesting acceleration and extended exercisability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176948,"accession_number":"0001723128-25-000009","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal reports Q4 revenue $731M (+18% YoY), FY24 revenue $2.79B (+17%); guides FY25 $3.0-3.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 GAAP net loss $31M ($0.10 diluted loss per share); adjusted net income $40M, adjusted EBITDA $155M.","Full year 2024 net revenue $2.79B (+17% YoY); GAAP net loss $117M; adjusted EBITDA $627M (+12% YoY).","All three segments (Affordable Medicines, AvKARE, Specialty) grew double-digits in FY24; CREXONT launched successfully.","FY25 guidance: net revenue $3.0-$3.1B, adjusted EBITDA $650-$675M; net leverage reduced to 3.9x a year ahead of target."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":2793957000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176947,"accession_number":"0001723128-25-000005","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["2.02","7.01"],"status":"ready","headline":"Amneal expects to meet or exceed 2024 full-year guidance; net leverage ~4x","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Expects to meet net revenue ($2.70-2.80B), adjusted EBITDA ($610-630M), and adjusted diluted EPS ($0.57-0.63).","Expects to exceed operating cash flow guidance ($280-320M) and capital expenditure guidance ($60-70M).","Estimates net leverage at approximately 4x as of December 31, 2024.","Guidance includes 100% of AvKARE EBITDA; adjusted EPS accounts for 35% non-controlling interest."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":2793957000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193742,"accession_number":"0001723128-24-000044","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K/A","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q3 net revenue up 13% to $702M; adjusted EBITDA $158M, guidance affirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $702M (+13% YoY); GAAP net loss ~$0.2M vs prior year net income of $10M.","Adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 prior year.","Generics +9%, Specialty +19% driven by CREXONT/ONGENTYS launches; AvKARE +21%.","Affirms full-year 2024 guidance; launched CREXONT, collaboration with Metsera, in-licensed biosimilar.","Higher interest expense drove GAAP net loss and lower adjusted EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2063439000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193744,"accession_number":"0001723128-24-000037","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q3 revenue up 13% to $702M; GAAP net loss $0.2M, adjusted EPS $0.16; affirms guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $702M (+13% YoY); adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 YoY.","GAAP net loss $0.2M vs net income $10M in Q3 2023; diluted EPS $0.00.","Generics +9%, Specialty +19%, AvKARE +21%; launched CREXONT for Parkinson's disease.","Collaboration with Metsera for obesity/metabolic drugs; in-licensed high-value biosimilar.","Affirms full-year 2024 guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2063439000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193743,"accession_number":"0001628280-24-041646","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Amneal and Metsera partner on obesity drug portfolio; new India facilities cost $150-200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amneal to build two manufacturing facilities in India for peptide synthesis and sterile fill-finish; net cost $150-200M over 4-5 years.","Amneal named Metsera's preferred supply partner for US and Europe; licensed to commercialize in select emerging markets.","Metsera's lead candidate MET-097 (GLP-1 injectable) showed durable weight loss in Phase 1; expected first drug under collaboration.","Collaboration leverages Amneal's existing manufacturing network and provides a new high-growth vector in the obesity market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210060,"accession_number":"0001723128-24-000030","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal beats Q2 estimates, raises FY guidance; FDA approves CREXONT for Parkinson's","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $702M (+17% YoY); GAAP net income $6M ($0.02 diluted EPS).","Adjusted EBITDA $162M (+11% YoY); adjusted diluted EPS $0.16 vs $0.19 prior year.","Raising full-year 2024 guidance on broad-based growth across all segments.","FDA approved CREXONT (carbidopa/levodopa) for Parkinson's disease; launch expected September 2024.","Specialty revenue +7%, Generics +14% (driven by biosimilars), AvKARE +33%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1360971000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228282,"accession_number":"0001628280-24-021107","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amneal shareholders elect all 11 directors, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; votes ranged from 238.7M (Meister) to 254.4M (Yanai) for.","Advisory vote on NEO compensation approved with 254.4M for, 1.2M against.","Ratification of Ernst & Young as auditor for FY2024 passed with 279.1M for, 0.6M against.","Broker non-votes of ~24.1M shares on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228281,"accession_number":"0001723128-24-000018","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q1 revenue $659M (+18% YoY); GAAP net loss $92M on $94M opioid charge","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $659M (+18% YoY); Generics +14%, Specialty +15%, AvKARE +33%.","GAAP net loss $92M ($0.30 loss per share) includes $94M pre-tax charge for nationwide opioids settlement in principle.","Adjusted EBITDA $152M (+31% YoY); adjusted diluted EPS $0.14 (vs $0.12 YoY).","Opioids settlement payable over ten years; company affirming 2024 full-year guidance.","All three segments posted double-digit revenue growth for first time in same quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":659191000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247013,"accession_number":"0001723128-24-000007","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal reports Q4 2023 net revenue $617M, GAAP loss $0.40 EPS; 2024 guidance $2.55-2.65B revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $617M (+1% YoY); GAAP net loss $99M ($0.40 loss per share); adjusted EBITDA $142M (-8% YoY).","Full year 2023 net revenue $2.39B (+8%); GAAP net loss $84M; adjusted EBITDA $558M (+$44M YoY).","2024 guidance: net revenue $2.55-$2.65B; adjusted EBITDA $580-$620M.","Generics Q4 revenue -9% YoY on order timing; AvKARE +38% on launches; Specialty +2%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247012,"accession_number":"0001723128-24-000003","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["2.02","7.01"],"status":"ready","headline":"Amneal reaffirms FY2023 guidance: revenue $2.37-2.42B, adj. EBITDA $540-550M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirmed 2023 guidance previously issued on Nov 7, 2023 at an investor conference on Jan 10, 2024.","Net revenue range $2.37-$2.42 billion; adjusted EBITDA $540-$550 million.","Adjusted diluted EPS $0.51-$0.58; operating cash flow $250-$280 million.","Capital expenditures $50-$60 million; weighted average diluted shares ~310 million.","Guidance includes 100% of AvKARE Adjusted EBITDA and 35% non-controlling interest in EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264451,"accession_number":"0001193125-23-296658","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Amneal to transfer stock exchange listing from NYSE to Nasdaq effective Dec 27, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Listing on NYSE ends at market close Dec 26; Nasdaq trading starts at market open Dec 27.","Common stock will continue to trade under symbol AMRX and join Nasdaq Composite and Nasdaq Biotechnology Index.","Voluntary delisting from NYSE approved by Board; no change in business operations or shareholder rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264445,"accession_number":"0001193125-23-296632","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K/A","filed_at":"2023-12-15T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Amneal files corrected bylaws as part of 8-K/A amendment to prior merger filing","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Amendment No.1 corrects Exhibit 3.2 (Amended and Restated Bylaws) from Nov 7, 2023 merger.","No other changes from original 8-K; all other exhibits remain unchanged.","Original 8-K reported merger agreements and related amendments to employment and governance documents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264450,"accession_number":"0001193125-23-277184","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Amneal refinances $2.13B term loans extending maturity to 2028; ABL facility upsized to $600M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $2.13B of existing term loans due 2025 for new term loans due 2028; remaining $192M old loans unchanged.","New term loan interest margin set at 5.50% (SOFR) vs 3.50% on old loans; 5% exchange fee paid to consenting lenders.","ABL revolving credit facility increased to $600M with maturity June 2, 2027; margins 1.25%-1.50% over SOFR.","No financial covenants in new term loan agreement; secured by substantially all assets of loan parties.","Transaction completed on Nov 14, 2023; total new term loans outstanding $2.35B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264446,"accession_number":"0001193125-23-272933","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K12B","filed_at":"2023-11-08T23:59:59+00:00","items":["1.01","3.01","5.03","8.01","3.02","3.03","5.01","5.02","9.01"],"status":"ready","headline":"Amneal completes UP-C elimination, new holding company becomes public issuer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Old Amneal became wholly-owned subsidiary of New Amneal; New Amneal renamed to Amneal Pharmaceuticals, Inc. and continues trading under AMRX.","Tax Receivable Agreement amended: Amneal Group's share of tax savings reduced from 85% to 75%.","Amneal OpCo's Fourth Amended LLC Agreement removes requirement for tax distributions to former members.","Directors and executive officers remain identical; shares continue trading on NYSE with same CUSIP.","152,116,890 shares of New Amneal Class A common stock issued in conversion of common units."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264449,"accession_number":"0001723128-23-000038","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q3 net revenue $620M (+14% YoY); adjusted EBITDA $154M (+22%); guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $620M (+14% YoY); GAAP net income $10M ($0.06 EPS) vs loss $0.02 in Q3 2022.","Adjusted net income $60M; adjusted EBITDA $154M (+22%); adjusted EPS $0.19 vs $0.14.","Generics revenue +12%, AvKARE +25%, Specialty +9%; all segments contributed to growth.","FY2023 guidance affirmed after previously being raised; on track to launch 40+ generics; IPX203 on track for 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":1776626000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264448,"accession_number":"0001723128-23-000035","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal raises FY 2023 guidance after Q3 prelim: rev $610-620M, adj EBITDA $150-155M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue prelim Q3 2023 $610-620M, up ~13% YoY.","Adjusted EBITDA $150-155M, up ~21% YoY; income before taxes $18-28M, substantially higher YoY.","Net leverage declined to ~4.6x from 5.3x at Dec 2022 due to higher profitability and debt reduction.","Full-year 2023 guidance raised; Co-CEOs cite momentum from generics, biosimilars, and AvKARE.","IPX203 for Parkinson's on track for potential 2024 launch."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":1776626000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264447,"accession_number":"0001193125-23-257254","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Amneal to eliminate Up-C structure, form NewCo; expects $30M annual tax-distribution savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Binding term sheet executed Oct. 16, 2023 to reorganize into single-class structure via new Delaware holding company (NewCo).","All existing Class A and Class B shares convert to NewCo Class A common stock; target completion November 2023.","Six-month 2023 tax-related cash distributions were $30M; elimination expected to improve cash flows and reduce debt.","Tax Receivable Agreement amended: Amneal Legacy Group's share of tax savings reduced from 85% to 75%; no cash consideration.","NewCo to trade under same ticker AMRX on NYSE; management and board unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281684,"accession_number":"0001723128-23-000027","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q2 revenue up 7% to $599M, net income $12M; raises 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $599M, +7% YoY; GAAP net income $12M vs loss $121M prior year.","Adjusted net income $57M, adjusted EBITDA $146M (+9% YoY), adjusted diluted EPS $0.19.","Raising 2023 full year guidance following strong H1 performance.","Growth driven by Generics (complex portfolio, biosimilars), AvKARE expansion, and Specialty.","Company addressing U.S. drug shortages as one of largest domestic manufacturers."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":1156586000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300616,"accession_number":"0001193125-23-149302","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Amneal settles derivative suit over KSP acquisition; royalty cut, governance changes","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Amneal agreed to reduce Kashiv royalties by 1.15% on three products until $11.5M NPV cap is reached.","Attorneys' fees capped at $2M, subject to court approval; settlement hearing set for July 25, 2023.","Governance changes include independent Delaware counsel for related-party transactions and stockholder vote on deals >$100M.","Deborah M. Autor added to Amneal board and Conflicts Committee as independent director.","Settlement resolves claims that 2021 KSP acquisition was unfair; no admission of wrongdoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300615,"accession_number":"0001723128-23-000023","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amneal shareholders elect all director nominees, approve compensation and incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected with at least 84% of votes cast in favor.","Advisory say-on-pay proposal approved with 97.4% of votes cast in favor.","Ratification of Ernst & Young as auditor approved with 99.4% of votes cast.","Amended & Restated 2018 Incentive Award Plan approved with 93.3% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300614,"accession_number":"0001723128-23-000017","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q1 revenue $558M (+12% YoY); adj. EBITDA $116M (+16%); reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $558M, up 12% YoY; driven by generics, specialty (Rytary, Unithroid), and AvKARE expansion.","Net loss $7M ($0.05 loss per share) vs $2M loss last year; adjusted EPS $0.12 flat YoY.","Adjusted EBITDA $116M, up 16% YoY; company reaffirms full-year 2023 guidance.","Fourth and largest injectables facility successfully inspected; IPX203 PDUFA date June 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":557540000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300613,"accession_number":"0001723128-23-000012","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal reports preliminary Q1 2023 revenue $550-560M (+12% YoY); affirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $550-560M, up ~12% YoY; loss before taxes $10M-$0 (improvement ~50%).","Adjusted EBITDA $115-120M, up ~18% YoY.","Long-term debt $2.692B; net debt reduced to $2.541B from $2.647B at Dec 31.","Management cites strong generics, biosimilars uptake, Rytary/Unithroid growth; IPX203 PDUFA June 30.","Full year 2023 financial guidance affirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":557540000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320583,"accession_number":"0001723128-23-000006","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q4 revenue $610M (+14% YoY), adj. EBITDA $154M; FY23 guidance $2.25-2.35B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net revenue $610M (+14% YoY); GAAP net loss $4M ($0.03 loss per share).","Q4 adjusted net income $71M, adjusted EBITDA $154M (+26% YoY), adjusted diluted EPS $0.23.","Full year 2022 net revenue $2.21B (+6% YoY); GAAP net loss $130M ($0.86 loss per share) including $263M Opana litigation charge.","Full year adjusted EBITDA $514M (+$2M YoY), adjusted diluted EPS $0.68.","2023 guidance: net revenue $2.25-2.35B, adjusted EBITDA $500-530M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320582,"accession_number":"0001193125-23-005141","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["2.02","7.01"],"status":"ready","headline":"Amneal reaffirms FY2022 guidance: revenue $2.15-2.25B, adj. EBITDA $500-520M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reaffirmed FY2022 net revenue guidance of $2.15B-$2.25B; no change from Nov 4, 2022.","Adjusted EBITDA forecast unchanged at $500M-$520M; adjusted diluted EPS $0.65-$0.70.","Operating cash flow guidance $200M-$225M; capex $65M-$75M; diluted shares ~305M.","Guidance includes 100% of AvKARE EBITDA; accounts for 35% non-controlling interest.","Opana ER antitrust litigation cash payments of ~$131M excluded from operating cash flow guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338727,"accession_number":"0001723128-22-000037","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q3 2022 revenue $546M (+3.2% YoY), adj. EBITDA $126M, adj. EPS $0.14","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $546M, up 3.2% from $529M in Q3 2021; GAAP net loss $3M (diluted EPS $(0.02)).","Adjusted EBITDA $126M, down 5.1% YoY; adjusted diluted EPS $0.14 vs $0.21 in prior year.","Full-year 2022 outlook maintained; management cites new product approvals and biosimilar launch momentum.","AvKARE delivered double-digit growth; Generics and Specialty segments remained consistent."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":1602545000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356082,"accession_number":"0001193125-22-238857","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2022-09-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Amneal appoints Gustavo Pesquin as EVP, Chief Commercial Officer – Specialty","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pesquin joins from Sanofi, where he was North America Head for General Medicines.","Base salary $525,000; target annual bonus 60% of base salary; RSU grant of $1,000,000 vesting over 4 years.","Severance: 150% of base salary plus pro-rata bonus and 18 months benefits if terminated without cause or for good reason.","Effective September 6, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356081,"accession_number":"0001723128-22-000028","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal Q2 2022: net loss $121M, revenue +5% to $559M; Opana settlement charge $263M","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q2 2022 net revenue $559M (+5% YoY); GAAP net loss $121M vs net income $15M in Q2 2021.","Adjusted EBITDA $135M (-6% YoY); adjusted diluted EPS $0.19 vs $0.23 in prior year.","Pre-tax charge of $263M for Opana ER antitrust litigation settlement recorded.","2022 adjusted EBITDA guidance updated; specific figure not disclosed in provided excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":1056988000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356080,"accession_number":"0001193125-22-210639","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Amneal appoints Deborah M. Autor to Board of Directors, effective July 29, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deborah M. Autor appointed independent director; will serve on Conflicts Committee.","Autor previously FDA Deputy Commissioner and Global Head at AstraZeneca and Mylan.","Board now comprises 11 directors following her appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356079,"accession_number":"0001193125-22-196582","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Amneal subsidiary settles Opana ER antitrust litigation for $265M; records Q2 charge","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Impax subsidiary agrees to pay $265M plus interest to settle Opana ER antitrust class actions.","Settlement covers direct purchaser, indirect purchaser, and individual claims in MDL.","Company to record pre-tax charge of approx. $265M in Q2 2022.","Payments to be made between 2022 and Jan 2024; funded by cash on hand, cash flow, and revolver.","Settlement is not an admission of liability; subject to court approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374419,"accession_number":"0001723128-22-000023","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Amneal refinances $500M credit facility with new $350M revolving facility maturing 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $350M senior secured revolving credit facility with Truist Bank as administrative agent; matures June 2, 2027.","Interest rates: ABR + 0.25% to 0.50% or SOFR + 1.25% to 1.50% per annum, depending on excess availability.","Includes $25M letter of credit subfacility and $35M swingline; incremental increase option up to $150M.","Prior $500M facility (due May 2023) terminated with no outstanding amounts and no termination penalties incurred.","Proceeds may be used for capex, acquisitions, working capital, and general purposes under customary negative covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374418,"accession_number":"0001723128-22-000019","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2022-05-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amneal stockholders elect all 10 director nominees, approve say-on-pay and auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected; Chintu Patel received highest votes (236,380,089 for).","Say-on-pay advisory vote approved: 236,202,110 for, 1,193,006 against.","Ratification of Ernst & Young as auditor for FY2022 approved: 256,967,689 for, 253,537 against.","Broker non-votes were 20,029,960 on director elections and say-on-pay; none on auditor ratification.","Annual meeting held May 9, 2022; all three proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374417,"accession_number":"0001723128-22-000012","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amneal reports Q1 2022 net revenue $498M (+1% YoY), GAAP net loss $2M, adj. EPS $0.12","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $498M vs $493M in Q1 2021; driven by generics and AvKARE distribution, partially offset by Zomig loss of exclusivity.","GAAP net loss $2M ($0.01 diluted loss per share) vs net income $7M in Q1 2021.","Adjusted EBITDA $100M including $5M R&D milestone expense; adjusted diluted EPS $0.12.","Company maintains 2022 full-year outlook; highlights FDA approvals for two biosimilars and Saol Baclofen acquisition.","Growth strategy focused on biosimilars, injectables, and advancing R&D pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":497633000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392945,"accession_number":"0001193125-22-077358","cik":1723128,"company_name":"Amneal Pharmaceuticals, Inc.","ticker":"AMRX","form_type":"8-K","filed_at":"2022-03-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Amneal EVP & Chief Commercial Officer–Specialty Joseph Todisco to depart by May 15, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Todisco is stepping down from his role as EVP, Chief Commercial Officer – Specialty.","He will remain through a transition period expected to end May 15, 2022.","Todisco is leaving to pursue an opportunity outside the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4126559393.7175283,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-16T23:59:59+00:00|392945"}